Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
Fierce Pharma
Mon, 01/13/20 - 11:01 am
Tags:
AstraZeneca, Amarin, Vascepa, Epanova, clinical trials
AstraZeneca gets in on RNA game with MiNA research collaboration
Endpoints
Tue, 01/7/20 - 10:39 am
Tags:
AstraZeneca, RNA, MiNA, R&D
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
Forbes
Tue, 01/7/20 - 10:34 am
Tags:
FDA, Lynparza, AstraZeneca, pancreatic cancer
AstraZeneca kicks off 2020 with double win in US and China
Pharmaforum
Mon, 01/6/20 - 10:23 am
Tags:
AstraZeneca, FDA, Farxiga, heart failure, China, Lokelma, hyperkalemia
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
Thu, 01/2/20 - 11:57 pm
Tags:
FDA, drug approvals, cancer, drug launches, AstraZeneca, Enhertu, Padcev, Seattle Genetics, BeiGene, Brukinsa
Corporate and regulatory developments over the Christmas period
EP Vantage
Thu, 01/2/20 - 11:39 pm
Tags:
Astellas, M&A, Qiagen, AstraZeneca, Bausch Health, BeiGene, Celyad, Immunomedics, Merck, Merck KGaA, Ono Pharmaceutical, Pfizer, Pharming, Xyphos Biosciences
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
BioSpace
Mon, 12/30/19 - 05:39 pm
Tags:
AstraZeneca, Merck, Lynparza, pancreatic cancer, FDA
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
Pharmaforum
Mon, 12/23/19 - 11:46 pm
Tags:
FDA, AstraZeneca, Daiichi Sankyo, advanced breast cancer, Enhertu
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
BioPharma Dive
Fri, 12/20/19 - 08:19 pm
Tags:
Daiichi Sankyo, AstraZeneca, FDA, drug approvals, breast cancer, trastuzumab deruxtecan
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
Thu, 12/19/19 - 11:32 pm
Tags:
oncology, Rare Diseases, AstraZeneca, GSK, Alexion, Takeda, Soliris
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Biopharma Dive
Thu, 12/19/19 - 01:05 pm
Tags:
AstraZeneca, lupus, anifrolumab, GSK, Benlysta
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
Tue, 12/17/19 - 09:19 pm
Tags:
AstraZeneca, Merck, Lynparza, pancreatic cancer, FDA, advisory panels
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Tue, 12/17/19 - 10:34 am
Tags:
Novartis, Europe, GSK, Sanofi, AstraZeneca, Roche
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia
Pharmaceutical Business Review
Tue, 12/17/19 - 10:25 am
Tags:
AstraZeneca, Seroquel, Seroquel XR, Russia, Europe, Cheplapharm
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Fierce Pharma
Mon, 12/16/19 - 10:42 am
Tags:
AstraZeneca, Merck, Lynparza, FDA, BRCA-mutated pancreatic cancer, pancreatic cancer
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Fri, 12/13/19 - 09:05 pm
Tags:
Eli Lilly, Boehringer Ingelheim, Jardiance, Farxiga, diabetes, AstraZeneca, heart failure
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
Thu, 12/12/19 - 10:55 am
Tags:
China, AstraZeneca, Imfinizi, non-small cell lung cancer
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
Wed, 12/11/19 - 10:24 am
Tags:
breast cancer, AstraZeneca, Daiichi Sankyo, SABCS, trastuzumab deruxtecan
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
Xconomy
Mon, 12/9/19 - 09:40 am
Tags:
AstraZeneca, Gatehouse Bio, R&D, Respiratory, Cardiovascular, sRNA
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
Pharmaforum
Sun, 12/8/19 - 10:17 pm
Tags:
AstraZeneca, cancer, Calquence, ASH2019, Imbruvica, JNJ, AbbVie, CLL

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.